4th Reverse Pitch Webinar: Collaboration Opportunities with Japanese Pharmaceutical Companies


10th July, 2024


09:00 - 10:35 UK Time


Online (Zoom)

Department for Business and Trade (DBT) Japan are delighted to host the 4th webinar inviting speakers from pre-clinical stage R&D / Business Development from the leading 6 Japanese pharmaceutical companies: Astellas Pharma Inc, Daiichi Sankyo Co Ltd, Eisai Co Ltd, Mitsubishi Tanabe Pharma Corporation, Shionogi & Co Ltd and Takeda Pharmaceutical Company Limited.  

This webinar, open to UK headquartered companies and universities, provides the ideal opportunity to learn the latest research priorities and collaboration structures of the leading Japanese pharmaceutical companies.

There is an opportunity to set up 1-2-1 online calls with the 6 speaker companies at a later date on request. The speakers’ contact details will become available after the webinar.  When contacting, please include 1) USP and any track record,  2) How your technology fits their research priorities, and 3) non-confidential slide deck to explain your proposal for potential collaboration. The presenters will discuss internally and get back to you only when they show initial interest in having a follow up meeting. Please copy the DBT Japan Life Sciences team in to your email (LS.Japan.trade@fco.gov.uk).


09:00               Opening Remarks / Housekeeping

09:05-09:20     Astellas Pharma Inc

09:20-09:35     Daiichi Sankyo Co Ltd

09:35-09:50     Eisai Co Ltd

09:50-10:05     Mitsubishi Tanabe Pharma Corporation

10:05-10:20     Shionogi & Co Ltd

10:20-10:35     Takeda Pharmaceutical Company Limited

10:35               Closing

*Q&A Moderator: Dr Ivana Poparic, Head of Life Sciences Cluster Development, MedCity / London & Partners


Pre-registration is required from here: 


<Key interest areas from the companies>

Astellas Pharma Inc

Astellas is interested in emerging areas of drug discovery & development including new biological insights, platforms, and modalities across multiple therapeutic areas.

  • Cell therapy programs using pluripotent stem cells and related technologies
  • AAV gene therapy projects and technologies
  • Novel immuno-oncology programs
  • Targeted protein degradation programs and technologies
  • New programs and technologies for immune regulation


Daiichi Sankyo Co Ltd

Daiichi Sankyo is seeking early-stage technology platform-based opportunities for research collaboration with academia or startups.


  • Cancer-specific neoantigens and their discovery technologies
  • Technologies for identification of molecular glue degraders
  • Antibodies or antibody-like binding molecules (e.g. Fab, scFv) against tumor tissue (e.g. tumor cells, immune cells, stromal cells)-specific targets


  • Novel therapeutic targets/pathways leading to drug discovery for psychiatric disorders
  • In vitro models of neuronal dysfunction for the discovery of novel therapeutic targets

Eisai Co Ltd


  • Modulation of the neuro-glia-vascular unit in the brain
  • Nerve regeneration without transplantation
  • Brain- or cell-specific delivery systems
  • Novel fluid biomarkers for neurodegenerative disease


  • New targets and concepts for the treatment of refractory cancers
  • Therapeutic targets and concepts for early intervention
  • Novel methodologies to make the undruggable targets druggable
  • Clinically relevant novel cancer models

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma is exploring for research collaboration and partnership opportunities for drug discovery technologies below, in addition to drug candidates and drug targets in our focused therapeutic areas of neurological/autoimmune diseases and refractory cancers.

Drug Discovery Technologies

  • Assay Systems required for screening and POC studies, Clinical Samples and Biomarkers for our targeting diseases
  • DDS for oligonucleotide therapeutics and RNA-targeted small molecules for Neurological Diseases
  • Bispecific Antibody and Cell Engagers acquisition technology for Autoimmune Diseases
  • Targeted protein degradations (TPD) or antibody drug conjugates (ADC) for refractory cancers

Shionogi & Co Ltd

  • Research collaboration and partnership opportunities in infectious diseases (esp. HIV, HBV, RSV, AMR, NTM*, Pandemic preparedness) and respiratory diseases
  • Research collaboration and partnership opportunities in dementia (symptomatic relief) and cognitive impairment
  • Research collaboration and partnership opportunities in sleep disorders (sleep apnoea), sensory loss (hearing loss) and mobility disorders (aging related)
  • Research collaboration and partnership opportunities in vaccine discovery
  • Phase 2 and 3 clinical assets in infectious diseases and CNS areas

(NTM*: Nontuberculous Mycobacteria)

Shionogi Wish List

Takeda Pharmaceutical Company Ltd

Takeda is seeking partners with innovative therapeutic candidates and technologies in the fields of Neuroscience, Oncology, and Gastrointestinal & Inflammation.

  • Neuroscience: Neurodegenerative diseases, neuromuscular diseases, Huntington’s disease and epilepsy
  • Oncology: Solid tumors, with preference toward lung and GI cancers
  • Gastrointestinal & Inflammation: Inflammatory diseases, fibrostenotic Crohn’s disease and advanced liver fibrosis (F3/F4 MASH)
  • Across all therapeutic areas: Novel target identification, single-cell profiling technologies, and translational patient datasets